Get the Stockscreener App
331.70
0.79%
2.61
After Hours:
331.70
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $331.70, with a volume of 1.76M.
It is up +0.79% in the last 24 hours and down -5.18% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$329.09
Open:
$329.48
24h Volume:
1.76M
Relative Volume:
0.64
Market Cap:
$179.12B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.07
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+0.57%
1M Performance:
-5.18%
6M Performance:
+3.59%
1Y Performance:
+21.93%
1-Day Range:
$328.00
$332.33
1-Week Range:
$320.52
$332.98
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
331.70 | 179.12B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
948.45 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.32 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
201.55 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
182.85 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.03 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Q1 2026 slides: six growth drivers fuel 24% expansion - Investing.com
Earnings call transcript: Amgen Q1 2026 beats EPS forecast, stock dips - Investing.com Canada
Amgen Inc. stock (US0311621009): U.S. manufacturing push and Q1 2026 results in focus - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Wesbanco Bank Inc. - MarketBeat
Amgen Inc. stock (US0311621009): Biotech giant eyes growth amid patent cliffs and pipeline bets - AD HOC NEWS
Crossmark Global Holdings Inc. Has $15.62 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Ethic Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF Case - simplywall.st
Is Amgen Stock Poised for a Rally? - Trefis
2 Dividend Stocks to Double Up On Right Now - The Motley Fool
FY2026 EPS Estimates for Amgen Boosted by Erste Group Bank - MarketBeat
Amgen Inc. Stock (US0311621009): Shares Dip After Strong Q1 2026 Earnings Beat and Analyst Downgrade - AD HOC NEWS
Amgen Inc. stock (US0311621009): Rating upgrade and Q1 beat amid tax and regulatory overhangs - AD HOC NEWS
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by Freedom Capital - MarketBeat
Generali Asset Management SPA SGR Raises Stake in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) EVP James Bradner granted RSUs, options; 407 shares withheld for taxes - Stock Titan
[Form 4] AMGEN INC Insider Trading Activity - Stock Titan
Amgen (AMGN) VP Matthew Busch granted RSUs and options, small tax share withholding - Stock Titan
Amgen (NASDAQ: AMGN) EVP gets major equity grants and tax share withholding - Stock Titan
Amgen (NASDAQ: AMGN) SVP receives RSU grant and 3,167 stock options - Stock Titan
Amgen (NASDAQ: AMGN) SVP receives 3,266 options and 500-share award - Stock Titan
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen (NASDAQ: AMGN) EVP Reese awarded RSUs, stock options and withholds shares for taxes - Stock Titan
Amgen (NASDAQ: AMGN) EVP receives RSUs, options and tax-withheld shares - Stock Titan
Amgen finance and R&D chiefs will speak in a public webcast May 13 - Stock Titan
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE - PR Newswire
Amgen Stock Falls Despite Strong Earnings: What's Driving the Decline? - MarketWise
Amgen stock rating upgraded to buy at Freedom Broker on growth - Investing.com
Swedbank AB Cuts Stake in Amgen Inc. $AMGN - MarketBeat
5 Must-Read Analyst Questions From Amgen’s Q1 Earnings Call - The Globe and Mail
Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery - Amgen
Amgen’s US$300m Biologics Push And What It Means For AMGN Stock - Yahoo Finance
Stevens Capital Management LP Invests $1.16 Million in Amgen Inc. $AMGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Principal Financial Group Inc. Has $200.10 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen’s Real Time FDA Trials Raise Questions On Pipeline Value - simplywall.st
Bokf Na Decreases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Alpha Cubed Investments LLC Sells 3,270 Shares of Amgen Inc. $AMGN - MarketBeat
AMGN Technical Analysis | Trend, Signals & Chart Patterns | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen (NASDAQ:AMGN) SVP Sells $400,454.01 in Stock - MarketBeat
Amgen SVP & CCO Nancy Grygiel sells $400,450 of company stock - Investing.com
Amgen (NASDAQ: AMGN) SVP sells 1,237 shares, retains 7,009 direct - Stock Titan
Amgen (AMGN) EVP Jonathan Graham reports 1,257 tax-withheld shares at $329.82 - Stock Titan
Amgen (NASDAQ: AMGN) CEO records 5,057-share equity tax withholding - Stock Titan
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Earnings call transcript: Amgen Q1 2026 surpasses EPS expectations - Investing.com
Earnings call transcript: Amgen Q1 2026 surpasses EPS expectations By Investing.com - Investing.com Canada
Erste Group Bank Reiterates Hold Rating for Amgen (NASDAQ:AMGN) - MarketBeat
Amgen announces multi-million dollar investment in Juncos - WJournalpr
What’s at stake in Amgen’s showdown with the FDA? - Pharma Voice
Amgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S Balance Sheet – TSX:AMGN - TradingView
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):